EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
Open Access
- 2 August 2023
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 37 (9) , 1925-1928
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Replicational Dilution of H3K27me3 in Mammalian Cells and the Role of Poised PromotersMolecular Cell, 2020
- Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple MyelomaCells, 2020
- Statistical determination of synergy based on Bliss definition of drugs independencePLOS ONE, 2019
- DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myelomaLeukemia, 2019
- EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiationLeukemia, 2019
- CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of ResistanceFrontiers in Immunology, 2018
- Genome Regulation by Polycomb and Trithorax: 70 Years and CountingCell, 2017
- Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumabBlood, 2017
- CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myelomaBlood, 2016
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyondImmunological Reviews, 2016